Physician profile
Theodore Tzeremas
NPI 1831252469
$5,709.40
in general payments reported to CMS, 2019-2025
36 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $248 · 2021: $614 · 2022: $1,120 · 2023: $888 · 2024: $1,183 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.88 |
| Education | $129.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $713.23 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $595.18 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $362.51 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $355.24 | 2020-2024 | Acthar, Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.64 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $320.99 | 2020-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $299.27 | 2022-2024 | Purified Cortrophin Gel |
| Amgen INC. | $264.35 | 2019-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $259.76 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $224.05 | 2021-2025 | Vafseo, Auryxia |
| Daiichi Sankyo INC. | $217.43 | 2021-2025 | Injectafer |
| Vifor Pharma, INC. | $215.20 | 2020-2023 | Veltassa |
| Travere Therapeutics, INC. | $213.14 | 2022-2025 | |
| Horizon Therapeutics Plc | $186.23 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $183.61 | 2020-2025 | Rayaldee |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Tzeremas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.